This web site is part of the Business Intelligence Division of Informa PLC
This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.
Clovis Oncology, Inc.
Drug Names(s): PF-1367338, PF-01367338, AG-14699, AG14699, CO-338
Description: Rucaparib is an oral, small molecule inhibitor of poly ADP-ribose polymerase 1 (PARP1), PARP2 and PARP3
Deal Structure: AG-14,699 was developed by Agouron Pharmaceuticals.
Warner-Lambert and Agouron
In May 1999, Warner-Lambert acquired Agouron Pharmaceuticals (Agouron).
Pfizer and Warner-Lambert
In June 2000, Pfizer completed its merger with Warner-Lambert.
Clovis and Pfizer
In June 2011, Clovis announced an agreement with Pfizer for the development and commercialization of PF-01367338.
Under the terms of the agreement, Clovis will take over responsibility for global product development and commercialization. Pfizer will receive an upfront license fee from Clovis, payable in equity in Clovis, and will be eligible to receive further payments totaling up to $255 million upon Clovis' successful attainment of development, regulatory and sales milestones. Pfizer will also receive royalties on any product sales. In addition, Pfizer will make a separate equity investment in Clovis Oncology.
Clovis and AstraZeneca
In April 2012, Clovis entered into a...See full deal structure in Biomedtracker
Partners: Pfizer Inc.
Additional information available to subscribers only: